NCT02023866 - Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Inherited Mitochondrial Disease, Including Leigh Syndrome

Interventions

DRUG

Cysteamine Bitartrate

Cysteamine Bitartrate Delayed-release capsules

Trial Locations (5)

Akron Children's Hospital, Akron

Baylor College of Medicine, Houston

University of Utah, Division of Medical Genetics, Salt Lake City

Stanford University, Stanford

University of California at San Diego (UCSD), San Diego